Healthcare Equipment and Supplies
Company Overview of Oxford Immunotec Global PLC
Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for the management of immune-regulated conditions. Its development activities principally focus on the areas of chronic infections, transplantation, autoimmune and inflammatory disease, and immune-oncology. The company develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immunologically controlled diseases. It offers T-SPOT.TB test, a single-cell based method for identifying latent tuberculosis infection. The company markets its T-SPOT.TB te...
115D Innovation Drive
Abingdon, OX14 4RZ
Founded in 2002
Key Executives for Oxford Immunotec Global PLC
Chief Executive Officer and Director
Total Annual Compensation: $414.5K
Chief Operations Officer
Total Annual Compensation: $293.5K
Chief Commercial Officer
Total Annual Compensation: $334.0K
Compensation as of Fiscal Year 2015.
Oxford Immunotec Global PLC Key Developments
Oxford Immunotec Global PLC Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2016; Revised Revenue Guidance for the Full Year 2016; Provides Revenue Guidance for the Third Quarter of 2016
Aug 2 16
Oxford Immunotec Global PLC reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2016. For the quarter, the company reported total revenue of $19.154 million compared to $14.252 million a year ago. Loss from operations was $7.335 million compared to $6.607 million a year ago. Loss before income taxes was $6.449 million compared to $7.293 million a year ago. Net loss was $6.446 million compared to $7.294 million a year ago. Basic and diluted net loss per share attributable to ordinary shareholders was $0.29 compared to $0.33 a year ago. LBITDA was $5.808 million compared to $6.791 million a year ago. Adjusted LBITDA was $5.292 million compared to $6.488 million a year ago.
For the six months, the company reported total revenue of $36.264 million compared to $28.053 million a year ago. Loss from operations was $14.529 million compared to $13.128 million a year ago. Loss before income taxes was $13.463 million compared to $13.557 million a year ago. Net loss was $13.495 million compared to $13.605 million a year ago. Net loss per share attributable to ordinary shareholders was $0.60 compared to $0.64 a year ago. LBITDA was $12.224 million compared to $12.587 million a year ago. Adjusted LBITDA was $11.071 million compared to $11.518 million a year ago.
The company expects to report full year 2016 revenue of between $82.5 million and $84.5 million as compared to prior guidance of between $79.5 million and $82.5 million.
The company expects to report revenue of between $24.2 million and $25.0 million for the third quarter of 2016.
Oxford Immunotec Global PLC Presents at Baird 2016 Global Healthcare Conference, Sep-07-2016 02:35 PM
Jul 26 16
Oxford Immunotec Global PLC Presents at Baird 2016 Global Healthcare Conference, Sep-07-2016 02:35 PM. Venue: The New York Palace, 455 Madison Avenue, New York, New York, United States. Speakers: Richard M. Altieri, Chief Financial Officer.
Oxford Immunotec Global PLC to Report Q2, 2016 Results on Aug 02, 2016
Jul 18 16
Oxford Immunotec Global PLC announced that they will report Q2, 2016 results at 9:00 AM, GMT Standard Time on Aug 02, 2016
Similar Private Companies By Industry
Recent Private Companies Transactions
June 23, 2016